Bill C-393 proposed, as Mr. Marc Garneau said, to remove schedule 1, which is a list of drugs that was contained in CAMR, the drugs that were eligible for manufacture and export under the regime. It also contained three lists of countries--so schedules 2 to 4.
The countries that were included were least developed countries, countries that were WTO members, and others. Each of those lists had varying responsibilities as per the WTO requirements and they were classified according to their pharmaceutical manufacturing capacity and their level of development.
My understanding of Bill C-393 would be that it would remove all four schedules, as per clause 15.